METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES Russian patent published in 2021 - IPC G01N33/52 G01N33/96 C12Q1/70 A61B5/145 

FIELD: biotechnology.

SUBSTANCE: proposed is method of enzyme immunoassay determination of the level of antigen-recognizing B-lymphocyte receptors represented by membrane antibodies specific to RBD Protein SARS-CoV-2, IgG. The method includes applying a recombinant RBD protein to the wells of the microplate corresponding to the structure of the RBD protein epitope of the SARS-CoV-2 virus, introducing calibration samples containing known amounts of IgG into the wells of the microplate, isolating and bringing the suspension of lymphocytes to the working concentration, introducing a suspension of lymphocytes into the wells of the microplate with antigen, introducing an IgG antibody conjugate, introducing TMB chromogen, conducting a color reaction, optical density spectrophotometry, construction of a calibration curve and determination of the concentration of SARS-CoV-2 IgG virus specific to RBD protein-antibodies relative to the optical density of calibration samples in the reference system.

EFFECT: invention makes it possible to detect in an infected person who has undergone COVID-19 or vaccinated, the level of specific neutralizing IgG antibodies to the RBD epitope of coronavirus, potentially characterizing the activity of B-lymphocyte receptors.

1 cl, 4 tbl